What it's for (Indications)
- Human insulin, including formulations combining regular and isophane insulin (such as Mixtard 30), is indicated for the treatment of diabetes mellitus in adults, adolescents, and children.
- This encompasses both Type 1 Diabetes Mellitus, where the body produces little to no insulin, and Type 2 Diabetes Mellitus, when hyperglycemia cannot be adequately controlled by diet, exercise, and oral hypoglycemic agents alone, or in situations where oral agents are contraindicated.
- This biphasic insulin formulation provides both a rapid-acting component to manage post-meal glucose excursions and an intermediate-acting component to provide basal glucose control throughout the day, offering a simplified insulin regimen for many patients requiring twice-daily dosing to achieve glycemic targets and prevent diabetes-related complications.
- Its use aims to improve glycemic control by facilitating glucose uptake into cells and inhibiting hepatic glucose production.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of insulin regular and isophane insulin, human (e.g., Mixtard 30) is highly individualized and must be determined by a healthcare professional based on the patient’s metabolic needs, blood glucose monitoring results, and lifestyle. This formulation is administered subcutaneously, typically 30 to 45 minutes before a meal (often breakfast and/or dinner), to ensure the rapid-acting component effectively covers the post-prandial rise in blood glucose. Patients are usually started on a low dose, for instance, 0.3-0.6 units/kg/day, divided into one or two injections, and then titrated based on frequent self-monitoring of blood glucose. It is crucial to rotate injection sites within the same region (e.g., abdomen, thigh, deltoid, buttocks) to minimize the risk of lipodystrophy. Patients must be thoroughly educated on proper injection technique, storage, and the importance of consistent meal timing relative to insulin administration to optimize efficacy and safety. |
Safety & Warnings
Common Side Effects
- The most common and clinically significant side effect associated with insulin therapy, including human regular and isophane insulin, is hypoglycemia.
- This can manifest as dizziness, sweating, tremor, confusion, palpitations, and in severe cases, seizures, coma, or death.
- Other potential side effects include localized reactions at the injection site such as pain, redness, swelling, itching, or bruising, which are usually transient.
- Lipodystrophy (lipoatrophy or lipohypertrophy) can occur at injection sites with repeated use if sites are not rotated adequately.
- Patients may also experience weight gain, peripheral edema due to fluid retention, and, rarely, generalized hypersensitivity reactions (e.
- g.
- , rash, urticaria, angioedema, bronchospasm, hypotension, shock).
- Hypokalemia, resulting from intracellular shifts of potassium, is another potential adverse effect that requires monitoring, particularly in vulnerable patient populations.
- Prompt recognition and management of these side effects are critical for patient safety.
Serious Warnings
- Black Box Warning: While insulin products, including formulations of human regular and isophane insulin, do not typically carry a formal FDA Black Box Warning, it is imperative to issue a serious warning regarding the profound risk of severe hypoglycemia. This constitutes the most frequent and life-threatening complication associated with insulin therapy. Unrecognized or untreated severe hypoglycemia can rapidly progress to loss of consciousness, seizures, permanent neurological damage, and can be fatal. Patients and caregivers must be educated extensively on the signs and symptoms of hypoglycemia, proper glucose monitoring, and the critical importance of prompt intervention (e.g., oral glucose, glucagon administration). Factors increasing the risk of severe hypoglycemia include inappropriate dosing, missed meals, increased physical activity, renal or hepatic impairment, and concomitant use of certain medications. This substantial risk warrants diligent patient education, individualized dosing, and continuous monitoring to mitigate serious adverse outcomes. The potential for these severe, life-threatening events underscores the need for careful medical supervision and patient adherence to prescribed regimens and self-management strategies.
- Patients receiving insulin regular and isophane insulin must be closely monitored for potential adverse reactions and complications.
- The most critical warning pertains to hypoglycemia, which can occur rapidly and lead to life-threatening consequences.
- Patients should be educated on the symptoms of hypoglycemia, self-monitoring of blood glucose, and appropriate corrective actions.
- Changes in insulin regimen, meal patterns, physical activity, or concurrent illness can significantly alter glucose levels and the risk of hypoglycemia.
- Co-administration with thiazolidinediones (TZDs) may increase the risk of fluid retention and heart failure, necessitating careful monitoring, especially in patients with pre-existing cardiac conditions.
- Allergic reactions, ranging from local site reactions to rare systemic anaphylaxis, are possible.
- Patients should never share insulin pens, needles, or syringes with others, even if the needle is changed, due to the risk of transmitting blood-borne pathogens.
- Careful attention to correct dosing is paramount, as dosage errors can lead to serious hypoglycemia or hyperglycemia.
- Drug interactions, especially with medications that can alter glucose metabolism (e.
- g.
- , beta-blockers, corticosteroids, diuretics), also warrant vigilance and dose adjustments.
How it Works (Mechanism of Action)
Insulin, a peptide hormone produced by the pancreatic beta cells, plays a pivotal role in regulating carbohydrate, fat, and protein metabolism. Its primary mechanism of action involves binding to specific insulin receptors on target cells (primarily muscle, adipose, and liver cells), initiating a cascade of intracellular events. This leads to increased cellular uptake of glucose from the bloodstream, largely by promoting the translocation of glucose transporters (e.g., GLUT4) to the cell membrane. Insulin also suppresses hepatic glucose production by inhibiting glycogenolysis and gluconeogenesis. Furthermore, it promotes the synthesis of glycogen in the liver and muscle, reduces lipolysis in adipocytes, thereby decreasing the release of free fatty acids, and enhances protein synthesis while inhibiting protein degradation. The specific formulation of insulin regular and isophane insulin provides a dual action: the regular insulin component offers a rapid onset (within 30-60 minutes) to cover post-prandial glucose, while the isophane insulin, an intermediate-acting form, provides prolonged basal glucose control through delayed absorption due to its crystallization with protamine.